Importantly, knock down of BCL11A in transgenic sickle cell disease mice stimulated therapeutic levels of fetal globin, suggesting the importance of BCL11A in hemoglobinopathy treatments [154]. This evidence concerns the gene BCL11A and hemoglobinopathy.